About CD Capital
CD Capital is a venture capital firm founded in 2013. It is primarily based out of Shanghai, China. As of May 2022, CD Capital has invested in 53 companies. It primarily invests in Series B round in China based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series A round of Fulian Pharmaceuticals Overall, CD Capital portfolio has seen 6 IPOs and 3 acquisitions including key companies like Microtech Medical, Berry Genomics and BMC Medical. A lot of funds co-invest with CD Capital, with names like Qianhai Ark Asset Management sharing a substantial percentage of its portfolio.Key Metrics
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Series A & 2 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
CD Capital's List of Top Investments
CD Capital has a portfolio of 53 companies. Their most notable investments are in SeekGene and West Lake.Their portfolio spans across China, United States and Taiwan. They have invested in Life Sciences, High Tech, Enterprise Applications and 5 other sectors, across stages such as Series B, Series A and 2 more. Here is the list of top investments by CD Capital:Microtech Medical is a developer of medical devices for diabetes care. It has developed three products i.e. glucose meters, test strips, and patch insulin pump. It also provides users with a mobile app to keep a check on blood glucose levels and insulin. It has raised a Series B round of funding.
Key facts about Microtech Medical
- Founded Year: 2011
- Location: Hangzhou (China)
- Stage: Public
- Total Funding till date: $88.2M
- Employee Count: 55 as on May 31, 2026
- Investors: 3H Health Investment, HEDA Ventures and 9 Others
- Latest Funding Round: Series C, Dec 09, 2020, $*****
- Highlight: Public
2. Inxmed
Developer of treatments for drug resistance and metastases in solid tumors. The company offers a chemotherapy approach and has its lead product IN10018 in phase 2 of the clinical study. It offers the treatment of platinum-resistant ovarian cancer, fallopian tube cancer, and primary peritoneal cancer by focal adhesion kinase (FAK) inhibitor. The company is also in Phase I of the clinical trial of IN10018 single agent and combined chemotherapy for the treatment of gastric cancer.
Key facts about Inxmed
- Founded Year: 2018
- Location: Shanghai (China)
- Stage: Series B
- Total Funding till date: $84M
- Employee Count: 16 as on May 31, 2026
- Investors: CD Capital, SDIC and 7 Others
- Latest Funding Round: Conventional Debt, Jul 21, 2022, $*****
- Highlight: Editors' Pick
Biotech company that develops and commercializes next-generation sequencing based integrated solutions for clinical applications. Focuses majorly on genetic testing and oncology testing. It is one of the leading providers of non-invasive prenatal testing (NIPT) in China. Its products include NextSeq CN500 gene sequencing platform and supply of consumables to the sequencing system. In Dec 2016, the company went public on China's Shenzhen market via a reverse merger with Chengdu Tianxing Instrument & Meter, a shell auto company, in a deal that values Berry Genomics at $618.8M.
Key facts about Berry Genomics
- Founded Year: 2010
- Location: Beijing (China)
- Stage: Public
- Total Funding till date: $16M
- Employee Count: 22 as on May 31, 2026
- Investors: Legend Capital, TMCP and 6 Others
- Latest Funding Round: Series B, Apr 02, 2015, $*****
- Highlight: Public
_1552046859915.png?format=webp&height=120&width=120){kind=logo}
Beijing Kangchen Pharmaceutical is a developer of antivenom drugs.
Key facts about Beijing Kangchen Pharmaceutical
- Founded Year: 2009
- Location: Beijing (China)
- Stage: Funding Raised
- Investors: CD Capital and Cowin Capital
_1557460587366.png?format=webp&height=120&width=120){kind=logo}
Manufacturer of flat panel X-ray detectors. The technology spans from amorphous Silicon (a-Si) to IGZO (Oxide TFT), flexible substrates, and CMOS devices. Their systems are used in medical, dental, veterinary, security, and industrial imaging applications.
Key facts about iRay Technology
CD Capital's Year-on-Year Investment Trends
CD Capital has invested in 53 companies over the last 11 years, with an average of 3 new investments annually in the last 10 years. Its most recent first time investment was in Fulian Pharmaceuticals and most recent follow-on round was in Huida.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 0 | 0 | 0 |
2024 | 0 | 0 | 0 |
2023 | 0 | 0 | 0 |
2022 | 4 | 2 | 6 |
2021 | 10 | 2 | 12 |
2020 | 4 | 1 | 5 |
2019 | 4 | 1 | 5 |
2018 | 5 | 0 | 5 |
2017 | 3 | 0 | 3 |
CD Capital's Investments by Stage
CD Capital has made 18 investments in Series B stage with an average round size of $25.1M, 11 investments in Series A stage with an average round size of $19.3M, 4 investments in Seed stage with an average round size of $947K and 1 investment in Series E stage.Stage of entry | No. of Investments |
|---|---|
Series B | 18 |
Series A | 11 |
Seed | 4 |
Series E | 1 |
Note: We have considered here, only first round of investments
CD Capital's Investments by Sector
CD Capital has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Enterprise Applications, HealthTech and Healthcare. Notably, it has invested in 44 Tech companies, 42 Enterprise (B2B) companies, 15 Tech hardware companies and at least 14 companies focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 25 |
High Tech | 10 |
Enterprise Applications | 6 |
HealthTech | 6 |
Healthcare | 4 |
Others | 9 |
Note: We have considered here, only first round of investments
CD Capital's Investments by Geography
CD Capital has made most investments in China (32), followed by United States where it has made 2 investments.Country | No. of Investments |
|---|---|
China | 32 |
United States | 2 |
Note: We have considered here, only first round of investments
CD Capital's recent investments
CD Capital has not made any investment in 2026 so far.Here are the most recent investments by CD Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
May 26, 2022 | China | Series A | 2408 | ||
May 19, 2022 | China | Seed | 8157 | ||
May 12, 2022 | China | Series C | 4703 | [+1] | |
Apr 01, 2022 | China | Series A | 7483 | [+2] | |
Mar 29, 2022 | China | Series C | 9277 | [+7] |
IPOs and Publicly Listed companies in CD Capital's Portfolio
6 of CD Capital's portfolio companies have become public. Aidite got listed on the Shenzhen Stock Exchange (SZSE), in Jun 2024 at marketcap of $471M and BMC Medical got listed on the Shenzhen Stock Exchange (SZSE) at marketcap of $1.09B.Here are CD Capital's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jun 26, 2024 | May 12, 2021 | Series B | 8349 | |
Nov 01, 2022 | - | - | 4945 | |
Oct 10, 2022 | May 28, 2021 | Series B | 1301 | |
Dec 23, 2021 | Nov 15, 2019 | Series B | 5919 | |
Oct 19, 2021 | Dec 09, 2016 | Series B | 8182 |
Acquired companies in CD Capital's Portfolio
3 companies from CD Capital's portfolio have been acquired. The most recent acquisition was Urotronic in Sep 2023 by Laborie Medical for $*****.Here are CD Capital's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Sep 06, 2023 | Aug 20, 2018 | Series B | 9764 | |
Mar 18, 2021 | Apr 02, 2018 | Series B | 9975 | |
Aug 19, 2018 | - | - | 6195 |
Co-investors of CD Capital
Over the past 11 years, 144 investors have co-invested in CD Capital's portfolio companies. This includes only funds.
- Invested before CD Capital: Matrix Partners China, Zhen Fund and 27 others have invested in rounds before CD Capital. There are 2 companies where Matrix Partners China has invested before CD Capital and 2 companies where Zhen Fund has invested before CD Capital.
- Top Co-investors of CD Capital: 60 investors entered a company along with CD Capital. These include investors like Qianhai Ark Asset Management (4 companies).
- Invested after CD Capital: A total of 55 investors have invested in CD Capital's portfolio after their investments. Top Investors include Kunlun Capital (2 companies), CICC Capital (2 companies) and Qianhai Ark Asset Management (2 companies).
Recent News related to CD Capital
•
"SprintRay Co." received over $100 million in Series D financing36Kr•Oct 09, 2022•SprintRay, SoftBank Vision Fund, Zhongwei Capital Management, CD Capital and 3 others
•
•
•
•
•
•
•
•
•
